About this trial
The CELESTIAL-RRCLL study is testing whether a new medicine called sonrotoclax, given with an antibody treatment, works better than a commonly used treatment for people whose CLL/SLL has come back or stopped responding to previous therapy. Researchers will compare how long each treatment keeps the cancer under control and how well patients respond to treatment. The study will also closely monitor side effects to understand the safety of the new treatment approach.
Patient Profile
This study is for adults with CLL or SLL whose cancer has returned or stopped responding after previous treatment. Participants have already received at least one earlier treatment and are generally well enough to undergo further therapy. Researchers are testing whether a new treatment combination containing sonrotoclax can help these patients better than a currently approved treatment
Where’s this trial being run?
St James’s Hospital, University Hospital Limerick, University Hospital Galway, and Mater Misericordiae University Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | CELESTIAL-RRCLL (BGB-11417-303) |
|---|---|
| Number: | 26-48 |
| Full Title: | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) |
| Principal Investigator: | Dr Anne Fortune |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | BeiGene |
| Recruitment Started: |
Global: June 2025 Ireland: Dec 2025 |
| Global Recruitment Target: | 630 |
|---|---|
| Ireland Recruitment Target: |